Clinical trials: Connective Tissue Diseases
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
The primary objectives of this study is to assess the safety, tolerability and efficacy of multiple doses of the mavrilimumab (CAM-3001) administered subcutaneously in subjects with moderately active Rheumatoid Arthritis (RA).
- Trial name
- NCT01050998
- Testing
- Mavrilimumab 10 mg, Mavrilimumab 30 mg, Mavrilimumab 50 mg
- Where
- 55 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 516 people
- Sponsor
- MedImmune LLC
Systemic Lupus Erythematosus (SLE)
CCCR Lupus Patient Navigator Program
To address the health disparities in SLE outcomes for minorities, targeted intervention will be used to address the common barriers to care among patients; a comprehensive patient navigator approach will be utilized based on…
- Trial name
- NCT04461158
- Testing
- Patient Navigator Services
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Medical University of South Carolina
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer
A Confirmation Study of Eribulin in Combination With Capecitabine
This is a Phase 1b/2, multi-center, open-label, dose escalation (in 2 different dosing schedules [1 and 2]) and dose-confirmation study of eribulin administered in combination with capecitabine.
- Trial name
- NCT01323530
- Testing
- Eribulin mesylate, Capecitabine
- Where
- 10 sites in Bulgaria, Russia and 1 more
- Volunteers
- 76 people
- Sponsor
- Eisai Limited
Breast Neoplasms
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
To investigate and compare the efficacy and safety of S-1 vs. Capecitabine as primary chemotherapy in patients with inoperable or recurrent breast cancer.
- Trial name
- NCT00438100
- Testing
- Capecitabine, S-1
- Where
- 8 sites in Japan
- Volunteers
- 142 people
- Sponsor
- Japan Breast Cancer Research Network
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- APEX (NCT04882098)
- Testing
- Guselkumab
- Where
- 280 sites in United States, Australia and 27 more
- Volunteers
- 1,054 people
- Sponsor
- Janssen Research & Development, LLC
Dupuytren's Contracture
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint…
- Trial name
- CORD-I (NCT00528606)
- Testing
- collagenase clostridium histolyticum
- Where
- 15 sites in United States
- Volunteers
- 308 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acne Vulgaris
A Treatment for Severe Inflammatory Acne Subjects
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a…
- Trial name
- NCT02899000
- Testing
- Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel, Oral doxycycline hyclate
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Galderma R&D
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Chronic Foot Ulcers
DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
A randomized versus placebo trial designed to evaluate the clinical and humoral effects of 4 months of vildagliptin on healing of chronic ulcers in type 2 diabetes.
- Trial name
- NCT01472432
- Testing
- vildagliptin
- Where
- Italy
- Volunteers
- 106 people
- Sponsor
- University of Campania Luigi Vanvitelli
CNS Cancer, Neuroblastoma
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9
The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten themselves to bacteria and viruses.
- Conditions
- CNS Cancer, Neuroblastoma, Sarcoma
- Trial name
- NCT00582608
- Testing
- 131I-8H9, 8H9
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Metastatic Breast Cancer
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01421017
- Testing
- Radiation, Imiquimod, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Psoriasis
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region
- Trial name
- NCT05789576
- Testing
- VTAMA (tapinarof) cream, 1%
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Gastrointestinal Stromal Tumor
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
This is a multicenter, non-randomized, single agent, Phase II study of AUY922 in patients with refractory Gastrointestinal Stromal Tumor (GIST).
- Trial name
- NCT01404650
- Testing
- AUY922
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- SCRI Development Innovations, LLC
Rheumatoid Arthritis, Plaque Psoriasis
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
- Trial name
- NCT01875991
- Testing
- Etanercept via Autoinjector A, Etanercept via Autoinjector B
- Where
- 37 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Amgen
Recurrent Melanoma, Stage IV Skin Melanoma
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
This randomized phase II trial is studying how well giving vaccine therapy together with or without recombinant interleukin-12 followed by daclizumab works in treating patients with melanoma that has spread to other places in the…
- Trial name
- NCT01307618
- Testing
- NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Rheumatoid Arthritis, Insulin Resistance
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA).
- Trial name
- RA PLUS (NCT01132118)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Skin Cancer
Post Excision/Mohs Scar Laser Resurfacing
The purpose of this study is to evaluate the potential benefits of treating a surgical scar post excision with an ablative fractionated CO2 laser with the goal of decreasing the appearance and size of the scar.
- Trial name
- NCT02130297
- Testing
- Laser Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in…
- Trial name
- NCT02027935
- Testing
- Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center